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Abstract
Background: Despite lithium’s being the most effective drug for bipolar disorder and in clinical use for decades,
we still know very little about its early effects relevant to its mode of action.
Methods/design: The Oxford Lithium Trial is a double-blind, randomised, placebo-controlled study of 6-week
lithium treatment in participants with bipolar disorder and mood instability. Its aim is to identify early clinical,
neurocognitive and biological effects. Participants (n = 40) will undergo an intensive battery of multi-modal
investigations, including remote monitoring of mood, activity and physiology, as well as cognitive testing, fMRI
and magnetoencephalography, together with biochemical and gene expression measurements to assess renal,
inflammatory and circadian effects.
Discussion: The findings derived from this trial may be of value in predicting subsequent therapeutic response or
side effects, not only relevant to the use of lithium but also providing a potential signature to help in more
rapid evaluation of novel mood stabilisers. In this respect, OxLith is a step towards the development of a valid
experimental medicine model for bipolar disorder.
Trial registration: ISRCTN91624955. Registered on 22 January 2015.
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Background
Bipolar disorder is a mood disorder which affects around
2 % of the population worldwide [1]. Lithium remains
the only pharmacological agent primarily indicated for the
treatment of bipolar disorder and has a robust evidence
base for efficacy, especially in the long term [2, 3]. It also
significantly reduces suicidal behaviour [4]. However, lith-
ium treatment has serious limitations, including toxicity in
overdose, many side effects and lack of efficacy in some
participants [5]. New treatments are urgently needed
because, despite its efficacy, many participants do not
respond to or cannot tolerate lithium, or have to stop
the drug due to toxicity. Moreover, the depressive episodes
of bipolar disorder are difficult to treat [6] and are
often prolonged, and, even when not meeting criteria
for a depressive or manic episode, participants often
have residual mood instability, cognitive difficulties and
other complaints [7]. Despite the widespread use of lithium
in bipolar disorder for over 50 years, we still know little
about its mechanism of action or about the early predictors
of therapeutic response. Such information would be of
value, both for optimising the clinical utility of lithium
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and in providing potential early markers of efficacy
which could be targeted in investigations of novel can-
didate mood stabilisers. At present, such investigations
require lengthy clinical trials which are expensive and
therefore risky [8, 9]. For example, the researchers in the
BALANCE trial, comparing lithium, divalproex and com-
bination lithium plus divalproex in the prevention of re-
lapse in bipolar disorder, followed participants for up to
2 years after randomisation, starting in 2000 and reported
in 2010 [10]. The field badly needs more proximal, early
or intermediate outcomes that can be used reliably in
early-phase trials to provide initial evidence of efficacy.
Together, the absence of validated targets and the conse-
quent difficulties of conducting clinical development pro-
grammes contribute to the dearth of therapeutic innovation
in this field.
Further, as more has been discovered about the typical
course of bipolar disorder, it has become clear that the
definition of bipolar disorder as an episodic condition in
which depression and mania are interspersed with nor-
mal mood (and its implication of normal functioning)
is over-simplistic and potentially misleading [11]. More
commonly, people with bipolar disorder experience
prominent inter-episodic sub-syndromal mood symptoms
[12, 13]. Indeed, there is increasing evidence that chronic
mood instability, which persists between clinically signifi-
cant mood episodes, is an important component of the
clinical picture [12]. Self-reported mood instability is a risk
factor for the emergence of bipolar disorder [14] and often
is a disabling feature for people with bipolar disorder,
particularly in those of young age or at the beginning
of their illness [15]. Reactivity of mood to external
events is also greater in bipolar disorder compared with
other mood disorders [16]. We have demonstrated the
realities of mood instability in participants, and how it can
be captured longitudinally at scale and over long periods of
time, using a mood-monitoring system called True Colours
(https://oxfordhealth.truecolours.nhs.uk/www/en/), [17];
other groups also have provided similar evidence [18, 19].
The Oxford Lithium Trial (OxLith) will take place within
our ongoing programme of research, the Collaborative
Network for Bipolar Research to Improve Outcomes
(CONBRIO), in which we are exploring the nature and
significance of mood instability.
On the basis of these data and considerations, we
hypothesise that persistent mood instability is a risk
factor for clinically significant mood episodes and that
better mood stabilisation may improve outcomes. If true,
and if robust markers of mood instability can be identi-
fied, this raises the possibility that measuring a change
in mood stability in response to lithium over a short
period such as a few weeks could predict long-term
therapeutic efficacy). In turn, this would be a major contri-
bution to the development of an experimental medicine
model allowing more rapid and efficient early-phase test-
ing of novel treatments, helping to overcome the current
impasse. A precedent is provided by the Oxford Emo-
tional Test Battery (ETB) [20], which facilitates early de-
tection of (and gives a cognitive model for) anti-
depressant efficacy. The ETB is a set of emotion-related
paradigms that have been shown to be sensitive to the
acute effects of anti-depressants and is now in use in de-
velopment programs for novel anti-depressant drugs. Im-
portantly, the ETB works in healthy subjects as well as in
participants with depression, enhancing its utility such
that, if our hypothesis is correct, novel bipolar disorder
treatments could also be tested in non-clinical populations
selected for high mood instability.
We have designed OxLith, an innovative randomised
controlled trial, to investigate the effects of lithium on
mood stability and on a wide range of cognitive, neural
and physiological indices. OxLith will take place within
CONBRIO, a research programme funded by the Well-
come Trust, which is seeking to (1) determine the nature
and significance of mood instability, its physiological
correlates, and the factors influencing it; (2) find novel
ways to measure mood stability in routine clinical practice
using a range of measures and devices; (3) apply mathem-
atically sophisticated methods for data analysis and inter-
pretation; and (4) develop an experimental medicine
model for mood stabilisation and bipolar disorder.
Methods/design
The schedule for the OxLith trial is displayed in Fig. 1.
Study objectives
The study objectives are as follows:
1. To compare the effects of lithium and placebo on
mood instability
2. To measure the cognitive effects of lithium and to
look for correlations with current mood state
3. To explore the effects of lithium on the variability in
neural dynamics during magnetoencephalography
(MEG) and functional magnetic resonance imaging
(fMRI) scans
4. To explore the effects of lithium on physical activity
and sleep
5. To explore the short-term effects of lithium on
gene expression; circadian hormones; and thyroid,
parathyroid and renal function
Study design
The trial is designed as a single-centre, prospective, ran-
domised, double-blind, placebo-controlled trial. Eligible
participants will be randomised in a 1:1 allocation to
lithium or placebo. The randomisation algorithm will
minimise separately on two variables age (<25 and
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≥25 years) and sex (male, female) which are related to
prognosis. Routine psychiatric follow-up with be ar-
ranged outside the trial as required. Participants will be
randomised following a 2-week run-in period and take
the study drug for 6 weeks.
Ethics
Written consent will be obtained from all participants.
The consent form will include agreement for the results
of any blood tests performed before consent to be used
as baseline measures for the trial, negating the need for
additional venepuncture. The study protocol was ap-
proved on 14 April 2015 by the National Research Ethics
Service Committee South Central – Oxford A (reference
number 15/SC/0109) and on 10 July 2015 by Oxford
Health NHS Foundation Trust.
Participants and recruitment
Participants will be recruited from the bipolar disorders
research clinic in Oxford. All participants will have a
diagnosis of bipolar disorder (I, II or not otherwise spe-
cified) based on the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, criteria and will re-
port clinically significant mood instability. In addition,
they will be individuals for whom there is uncertainty
about the benefits of lithium (for example, for an
individual who has recently been diagnosed or has had
relatively few major mood episodes). Participants will be
aged 18 years or older; will have pre-treatment renal,
cardiac, thyroid and parathyroid function acceptable for
the initiation of lithium; and will be willing and able to
consent to participate in the trial. Exclusion criteria in-
clude any contraindication to taking lithium, concomitant
psychotropic medication which cannot be withdrawn,
clinically significant substance abuse, the need for
treatment of an acute mood episode where placebo
would be unethical, pregnancy or being of childbearing
age not using effective contraception, and current suicidal
ideation.
Interventions
The interventions are placebo or lithium carbonate
200-mg prolonged release tablets are to be taken orally at
night and titrated to target serum level of 0.7 mmol/L.
This dosing is consistent with routine practice.
Measures
Primary outcome
The primary outcome will be mood severity and stability
over the 6-week randomised period as measured using a
quick inventory of depressive symptoms (16-item Quick
Inventory of Depressive Symptoms–Self-Rated), the Altman
Self-Rating Mania Scale and daily mood measures recorded
using the short form of the Positive and Negative Affect
Schedule (PANAS).
Fig. 1 OxLith trial schedule. ECG electrocardiogram
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Secondary outcomes
Cognition and neural dynamics Cognitive task per-
formance and neural dynamics will be measured to iden-
tify the effects of lithium on physiological variability and
to explore the relationship between this variability and
the experience of mood instability. The outcome mea-
sures will be (1) cognitive task performance for decision
making, implicit and explicit reinforcement learning
(completed daily using a smart device) in relation to
variability in daily measures of mood (PANAS), and (2)
the results of two brain scans, one using MEG and the
other fMRI. Both will include scans during resting state
and whilst performing a decision-making task similar to
one of the daily outcomes. Scans will be performed be-
tween 3 and 4 weeks post-randomisation when the lith-
ium level has reached a steady state.
Sleep and motor activation Participants will wear an
ActiGraph monitor (ActiGraph, Pensacola, FL, USA) for
the duration of the study. This will allow us to monitor
daytime activity and sleep patterns.
Circadian system We will monitor circadian gene ex-
pression (including BMALL , PER 1 and PER 2) and
genes targeted by lithium (e.g., GSK3, IMP and GAD L1)
collected from the cheek. Circadian controlled hormones
(cortisol and melatonin) will also be collected from
saliva to explore the relationship between the circadian
system, mood stability and lithium. Gene expression,
melatonin and cortisol levels will all be measured every
4 h over two separate 32-h periods, one prior to ran-
domisation and the other between weeks 3 and 4 post-
randomisation.
Physiological effects of lithium Blood samples will be
collected pre-randomisation and at the end of the rando-
mised phase to explore changes in a number of known bio-
markers related to thyroid (thyroid-stimulating hormone,
thyroid antibodies, triiodothyronine and free thyroxine),
parathyroid (parathyroid hormone, calcium and vitamin D)
and renal function (urea, creatinine, potassium, glomerular
filtration rate, neutrophil gelatinase-associated lipocalin
and cystatin C). Blood samples will also be used to explore
lithium-associated changes in intracellular protein compos-
ition and structure.
Power analysis and sample size
The target sample size is 40 participants (20 of whom will
be allocated to treatment with lithium and 20 to placebo).
This sample size will give more than 90 % power to detect
differences between groups on the main mood outcomes
at a significance level of 0.5 %. Pragmatically, this sample
size is achievable.
Blinding
All trial psychiatrists and participants will be blinded.
For those participants taking placebo, sham lithium level
results will be presented to the trial psychiatrist by an
unblinded researcher. The sham results will be based
upon information about reported adherence, time since
most recent dose, and adverse events. At or just before
the 6-week visit, the unblinded researcher will reveal the
participant’s allocated treatment to enable the participant
and psychiatrist to discuss treatment options. In the event
of a medical emergency, routine care for a patient who
may have been taking lithium and has symptoms consist-
ent with lithium toxicity would be to obtain a lithium level
immediately, thus negating the need for the treating
doctor to be informed about the trial allocation.
Statistical analysis plan
Multiple pre- and post-randomisation mood measure-
ments will be used in an analysis of covariance model to
compare lithium with placebo. Methods from the fMRIB
Statistical Library (FSL) will be used to analyse fMRI
data. The FSL is a software library containing image ana-
lysis and statistical tools for functional, structural and
diffusion magnetic resonance imaging brain data. MEG
data will be analysed using a generalised linear model
(GLM) and analysis of variance. The GLM method is a
standard non-linear beam former used to determine the
time course of neuronal activation for each point in a
predefined source space. Actigraphy data will be corre-
lated with mood and cognitive data.
In addition to these more traditional approaches to
analysis, we will apply linear and non-linear time series
methods and other advanced mathematical approaches,
including machine learning. These techniques can produce
binary or multi-level classifications as well as point and
density forecasts to quantify confidence intervals. We will
also apply the mathematical theory of rough paths [21],
providing a method to reduce datasets from complex
non-linear systems subjected to rapidly fluctuating
stimuli to their critical information, facilitating classifica-
tion and prediction.
Dissemination
Regardless of the magnitude or direction of effect, the
main findings of the trial will be compiled and pub-
lished in an appropriate journal and made available to
participants.
Discussion
OxLith has two main goals. The first is to better
characterise the early effects and mechanism of action of
lithium, together with its tolerability profile, compared
with placebo. The second is to establish whether mood in-
stability, of a higher frequency than clinical episodes of
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depression or mania, is sensitive to lithium. The explora-
tory design of OxLith is intended to provide a paradigm
and generate new experimental medicine outcomes and
methods which can be used to expedite the development
of new medicines for bipolar disorder. Drugs such as
ebselen which have effects similar to those of lithium in
vitro and in available mouse models of bipolar disorder
are likely early candidates for such approaches.
Trial status
Recruitment has started. The duration of the study is
3 years.
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